Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.

• Authors: Amarendra Pegu, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Sarah O'Connell, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Stephen D Schmidt, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Sijy O'Dell, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Chloe A Talana, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Lilin Lai, Emory University; Jim Albert, Emmes Company; Rockville, MD, USA.; Evan Anderson, Emory University; Hamilton Bennett, Moderna, Inc.; Cambridge, MA, USA.; Kizzmekia S Corbett, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Britta Flach, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Lisa Jackson, Kaiser Permanente Washington Health Research Institute; Seattle, WA, USA.; Brett Leav, Moderna, Inc.; Cambridge, MA, USA.; Julie E Ledgerwood, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Catherine J Luke, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA.; Mat Makowski, Emmes Company; Rockville, MD, USA.; Paul C Roberts, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA.; Mario Roederer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Paulina Rebolledo, Emory University; Christina Rostad, Emory University; Nadine Rouphael, Emory University; Wei Shi, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Lingshu Wang, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Alicia T Widge, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Eun Sung Yang, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; John H Beigel, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA.; Barney S Graham, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; John R Mascola, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Mehul Suthar, Emory University; Adrian McDermott, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.; Nicole A Doria-Rose, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda MD, USA.
• Journal Title: bioRxiv
• Publisher: bioRxiv | 2021-05-16
• Type of Work: Article | Preprint: Prior to Peer Review
• Publisher DOI: http://doi.org/10.1101/2021.05.13.444010
• Subjects: Biology, Microbiology
• Keywords: mRNA-1273; SARS-CoV-2 variants; antibodies

Abstract

SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-blocking antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose of mRNA-1273. At the peak of response to the second dose, all subjects had robust responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of mRNA-1273. Across all assays, B.1.351 had the greatest impact on antibody recognition, and B.1.1.7 the least. These data complement ongoing studies of clinical protection to inform the potential need for additional boost vaccinations. ONE-SENTENCE SUMMARY: Most mRNA-1273 vaccinated individuals maintained binding and functional antibodies against SARS-CoV-2 variants for 6 months.